Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in young patients: a multi-institutional study

Purpose Surgery is the treatment of choice for large vestibular schwannomas (VS). Stereotactic radiosurgery (SRS) has been suggested as an alternative to resection in selected patients. However, the safety and efficacy of SRS in Koos grade IV patients <= 45 years old has not been evaluated. The aim of this study is to describe the clinical and radiological outcomes of Koos grade IV in young patient managed with a single-session SRS. Methods This retrospective, multicenter analysis included SRS-treated patients, <= 45 years old presenting with non-life threatening or incapacitating symptoms due to a Koos Grade IV VS and with follow-up >= 12 months. Tumor control and neurological outcomes were evaluated. Results 176 patients [median age of 36.0 (IQR 9) and median tumor volume of 9.3 cm(3) (IQR 4.7)] were included. The median prescription dose was 12 Gy (IQR 0.5). Median follow-up period was 37.5 (IQR 53.5) months. The 5- and 10-year progression-free survival was 90.9% and 86.7%. Early tumor enlargement occurred in 10.9% of cases and was associated with tumor progression at the last follow-up. The probability of serviceable hearing preservation at 5- and 10-years was 56.8% and 45.2%, respectively. The probability of improvement or preservation of facial nerve function was 95.7% at 5 and 10-years. Adverse radiation effects were noted in 19.9%. New-onset hydrocephalus occurred in 4.0%. Conclusion Single-session SRS is a safe and effective alternative to surgical resection in selected patients <= 45 years old particularly those with medical co-morbidities and those who decline resection. Longer term follow up is warranted.

Automated summary

Single-session SRS is a safe and effective alternative to surgical resection in selected patients <= 45 years old, especially for those with medical co-morbidities and who decline resection. The treatment showed good tumor control and neurological outcomes, with some cases experiencing early tumor enlargement, adverse radiation effects, and new-onset hydrocephalus.